0001610618-24-000016.txt : 20240312 0001610618-24-000016.hdr.sgml : 20240312 20240312214808 ACCESSION NUMBER: 0001610618-24-000016 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240311 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tari Leslie CENTRAL INDEX KEY: 0001870270 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36912 FILM NUMBER: 24744446 MAIL ADDRESS: STREET 1: C/O CIDARA THERAPEUTICS, INC. STREET 2: 6310 NANCY RIDGE DR SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 4 1 wk-form4_1710294467.xml FORM 4 X0508 4 2024-03-11 0 0001610618 Cidara Therapeutics, Inc. CDTX 0001870270 Tari Leslie 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 0 1 0 0 CHIEF SCIENTIFIC OFFICER 0 Common Stock 2024-03-11 4 S 0 21029 0.6698 D 258681 D Common Stock 1484 I By spouse The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on November 20, 2023. /s/ Shane Ward, Attorney-in-Fact 2024-03-12